pubmed-article:8471333 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8471333 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
pubmed-article:8471333 | lifeskim:mentions | umls-concept:C1151722 | lld:lifeskim |
pubmed-article:8471333 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:8471333 | pubmed:dateCreated | 1993-5-18 | lld:pubmed |
pubmed-article:8471333 | pubmed:abstractText | Dihydropyrimidine dehydrogenase (DPD) is the major catabolic enzyme of pyrimidines and fluoropyrimidines. The clinical course of 2 patients with suspected DPD deficiency is described. Both patients had significantly delayed clearance of fluorouracil (5-FU), elevated plasma uracil concentrations, and subsequent lethal toxicity. The prevalence of DPD deficiency in the general population is unknown, but given the large number of cancer patients treated with 5-FU, it may be of great clinical significance. Lymphocytes have been previously shown to be a useful marker of systemic DPD activity. Because DPD activity has not been previously reported in a large population of cancer patients using 5-FU as the substrate, we determined DPD activity in lymphocytes from 66 patients with cancer. DPD activity was determined by a sensitive high performance liquid chromatography method. The mean DPD activity (S.D.) in 66 patients with head and neck cancer was 0.189 (0.071) nomol/min/mg protein with wide interpatient variability (range 0.058-0.357). DPD activity was not correlated to age (r = -0.164, P = 0.188). The mean DPD activity in men [0.192 (0.074)] was not significantly different from that in women [0.172 (0.057); t-test P = 0.418]. Likewise, there was no statistical difference in DPD activity in patients who had not received prior chemotherapy [0.195 (0.066)] to patients receiving one or more cycles of chemotherapy [0.186 (0.074); t-test P = 0.638]. | lld:pubmed |
pubmed-article:8471333 | pubmed:language | eng | lld:pubmed |
pubmed-article:8471333 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8471333 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8471333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8471333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8471333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8471333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8471333 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8471333 | pubmed:issn | 0959-8049 | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:SchneiderMM | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:DemardFF | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:PlagneRR | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:FlemingR ARA | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:ThyssAA | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:SEGALM LML | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:GaspardM HMH | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:MilanoG AGA | lld:pubmed |
pubmed-article:8471333 | pubmed:author | pubmed-author:BargnouxP JPJ | lld:pubmed |
pubmed-article:8471333 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8471333 | pubmed:volume | 29A | lld:pubmed |
pubmed-article:8471333 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8471333 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8471333 | pubmed:pagination | 740-4 | lld:pubmed |
pubmed-article:8471333 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:meshHeading | pubmed-meshheading:8471333-... | lld:pubmed |
pubmed-article:8471333 | pubmed:year | 1993 | lld:pubmed |
pubmed-article:8471333 | pubmed:articleTitle | Dihydropyrimidine dehydrogenase activity in cancer patients. | lld:pubmed |
pubmed-article:8471333 | pubmed:affiliation | Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice, France. | lld:pubmed |
pubmed-article:8471333 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8471333 | pubmed:publicationType | Case Reports | lld:pubmed |
pubmed-article:8471333 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8471333 | lld:pubmed |